FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:974-975 March 30, 2000 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Ziesche, R. PubMed Citation

To the Editor: Ziesche et al. (Oct. 21 issue)¹ report the findings of a preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. Given that there is no successful medical therapy for idiopathic pulmonary fibrosis, with only lung transplantation holding promise for long-term survival, the authors deserve credit for performing this pilot project. Unfortunately, their findings do not justify the enthusiasm that this article has generated in the media and among people with this disease.

First, it is unclear that the patients studied had idiopathic pulmonary fibrosis.² The disease is uncommon; consequently, . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Wells, A U, Hirani, N, on behalf of the BTS Interstitial Lung Disease Gui, (2008). Interstitial lung disease guideline. Thorax 63: v1-v58 [Full Text]  
• Clement, A., committee members, (2004). Task force on chronic interstitial lung disease in immunocompetent children. Eur Respir J 24: 686-697 [Abstract] [Full Text]  
• Kalra, S., Utz, J. P., Ryu, J. H., Mayo Clinic Interstitial Lung Diseases Group, (2003). Interferon Gamma-1b Therapy for Advanced Idiopathic Pulmonary Fibrosis. Mayo Clin Proc. 78: 1082-1087 [Abstract]